Share ownership MannKind Corporation

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
5.660 ^USD	+0.53%		-2.08%	-0.18%

02-09	MannKind Enrolls First Patient in Study Evaluating Afrezza Inhaled Insulin in Youth	MT
02-09	Mannkind Corporation Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza®? for Youth with Newly-Diagnosed Type 1 Diabetes	CI

Share class: MannKind Corporation

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	275,777,693	270,740,474 ( 98.17 %)	0	98.17 %

Major shareholders: MannKind Corporation

Name	Equities	%	Valuation
BlackRock Advisors LLC 8.751 %	26,872,119	8.751 %	155 M $
Vanguard Fiduciary Trust Co. 5.823 %	17,880,873	5.823 %	103 M $
Rubric Capital Management LP 3.717 %	11,414,671	3.717 %	66 M $
STATE STREET CORPORATION 3.498 %	10,740,198	3.498 %	62 M $
Geode Capital Management LLC 2.401 %	7,374,138	2.401 %	43 M $
Nitorum Capital LP 2.137 %	6,561,465	2.137 %	38 M $
UBS Financial Services, Inc. 1.66 %	5,098,375	1.66 %	29 M $
Avoro Capital Advisor LLC 1.455 %	4,468,877	1.455 %	26 M $
DFA Australia Ltd. 1.393 %	4,276,754	1.393 %	25 M $
Morgan Stanley Capital Services LLC 1.254 %	3,850,451	1.254 %	22 M $
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	47.42%
Other	4.93%
State Street Corp.	3.5%
Individuals	2.6%
Schweizerische Nationalbank	0.19%
Manulife Financial Corp.	0.05%
SEI Investments Co.	0.03%
Governments	0.03%
Unknown	41.25%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	50.23%
United Kingdom	3.01%
Individuals	2.6%
Australia	1.4%
France	0.85%
Switzerland	0.24%
Canada	0.2%
Ireland	0.06%
Germany	0.04%
China	0.03%
Hong Kong	0.02%
Finland	0.02%
Japan	0.02%
Norway	0.02%

Based on 1000 largest holdings

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Employees

405

Sector

Biotechnology & Medical Research

Calendar

03-02 - Q4 2025 Earnings Release (Projected)

More about the company